ATR is a key mediator of the cellular response to replication stress, helping maintain genome integrity during DNA replication. Inhibiting ATR compromises these protective mechanisms, creating a therapeutic vulnerability that is particularly pronounced in ATM-deficient tumors. Researchers at the Hefei Institute of Pharmaceutical Industry reported the identification of a novel series of proteolysis targeting chimeras (PROTACs) designed to induce ATR degradation.